Jeffrey Sevigny

1.4k total citations · 1 hit paper
17 papers, 876 citations indexed

About

Jeffrey Sevigny is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Jeffrey Sevigny has authored 17 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 5 papers in Psychiatry and Mental health and 3 papers in Molecular Biology. Recurrent topics in Jeffrey Sevigny's work include Alzheimer's disease research and treatments (7 papers), Dementia and Cognitive Impairment Research (5 papers) and HIV Research and Treatment (3 papers). Jeffrey Sevigny is often cited by papers focused on Alzheimer's disease research and treatments (7 papers), Dementia and Cognitive Impairment Research (5 papers) and HIV Research and Treatment (3 papers). Jeffrey Sevigny collaborates with scholars based in United States, Switzerland and United Kingdom. Jeffrey Sevigny's co-authors include Harald Hampel, Kaj Blennow, Richard Batrla, José Luís Molinuevo, Tobias Bittner, Holly Soares, Michelle M. Mielke, John Q. Trojanowski, Sid E. O’Bryant and Leslie M. Shaw and has published in prestigious journals such as Neurology, Schizophrenia Bulletin and Acta Neuropathologica.

In The Last Decade

Jeffrey Sevigny

15 papers receiving 859 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Current state of Alzheimer’s fluid biomarkers

2018 375 citations José Luís Molinuevo, Scott Ayton et al. Acta Neuropathologica profile →

Peers

Countries citing papers authored by Jeffrey Sevigny

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Sevigny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Sevigny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Sevigny more than expected).

Fields of papers citing papers by Jeffrey Sevigny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Sevigny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Sevigny. The network helps show where Jeffrey Sevigny may publish in the future.

Co-authorship network of co-authors of Jeffrey Sevigny

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Sevigny. A scholar is included among the top collaborators of Jeffrey Sevigny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Sevigny. Jeffrey Sevigny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Phase 1/2 dose-finding study to evaluate systemic administration of an AAV9-based gene therapy for peripheral manifestation of Gaucher disease: The PROCEED study 2025 ·Molecular Genetics and Metabolism ·Sarah Neuhaus, Marjorie Weaver, (unknown), Jennifer L. Cohen, Pilar Giraldo, (unknown), Lee Shaughnessy, (unknown), (unknown), Jeffrey Sevigny	0
2	Design of Phase 1/2a Study of AAV9-Based Gene Therapy for Parkinson’s Disease with Pathogenic GBA1 Mutations (PROPEL Trial) (1624) 2020 ·Neurology ·(unknown), Erin Mahoney, Lynne Verselis, Mark Lowrey, (unknown), Jeffrey Sevigny	2
3	Current state of Alzheimer’s fluid biomarkers breakdown → 2018 ·Acta Neuropathologica ·José Luís Molinuevo, Scott Ayton, Richard Batrla, Martin M. Bednar, Tobias Bittner, Jeffrey L. Cummings, Anne M. Fagan, Harald Hampel, Michelle M. Mielke, Alvydas Mikulskis, Sid E. O’Bryant, Philip Scheltens, Jeffrey Sevigny, Leslie M. Shaw, Holly Soares, Gary Tong, John Q. Trojanowski, Henrik Zetterberg, Kaj Blennow	375
4	S43. A PROOF-OF-MECHANISM STUDY OF THE PDE10 INHIBITOR RG7203 IN PATIENTS WITH PROBING REWARD FUNCTIONS WITH IMAGING AND BEHAVIORAL APPROACHES 2018 ·Schizophrenia Bulletin ·Daniel Umbricht, Juergen Dukart, Markus Abt, (unknown), Chris Chatham, Michael J. Frank, Anne Collins, David P. Walling, (unknown), Daniel Gruener, Lev Gertsik, Jeffrey Sevigny	2
5	Combination therapy for Alzheimer's disease: Are we ready? 2018 ·Alzheimer s & Dementia ·Stephen Salloway, Jeffrey Sevigny, Lisa J. Bain, James A. Hendrix, María C. Carrillo	1
6	Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II 2017 ·Autism Research ·Chris Chatham, Kirsten I. Taylor, Tony Charman, Xavier Liogier D’ardhuy, (unknown), Angie Fedele, Antonio Y. Hardan, Eva Loth, Lorraine Murtagh, Marta del Valle Rubido, Antonia San José Cáceres, Jeffrey Sevigny, Linmarie Sikich, (unknown), Julian Tillmann, Pamela Ventola, Karen Walton–Bowen, (unknown), Thomas Willgoss, Federico Bolognani	95
7	Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003) 2016 ·Neurology ·Vissia Viglietta, John O’Gorman, Leslie Williams, Ying Tian, Alfred Sandrock, Rachelle S. Doody, Stephen Salloway, Frederik Barkhof, Bruno Vellas, Mary Sano, Paul Aisen, Jeffrey Sevigny	9
8	Optimizing Central Nervous System Drug Development Using Molecular Imaging 2015 ·Clinical Pharmacology & Therapeutics ·RJ Hargreaves, Jack Hoppin, Jeffrey Sevigny, Shil Patel, Ping-Chun Chiao, Michael Klimas, Ajay Verma	22
9	Randomized, placebo-controlled, phase 1b study of anti-beta-amyloid antibody aducanumab (biib037) in prodromal ad/mild ad dementia: Interim results by patient subgroup 2015 ·Journal of the Neurological Sciences ·Jeffrey Sevigny, Ping-Chun Chiao, Leslie Williams, Tianle Chen, Ling Yan, John O’Gorman, C. Hock, Roger M. Nitsch, Alfred Sandrock	1
10	P3‐275: Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients 2010 ·Alzheimer s & Dementia ·Ana Graf, Niels Andreasen, Marie‐Emmanuelle Riviere, Jacqueline Ros, (unknown), Jeffrey Sevigny, Peter Quarg, Angelika Caputo, Luca A. Finelli, Bengt Winblad, Georges Imbert	2
11	Review: Item Analysis of ADAS-Cog: Effect of Baseline Cognitive Impairment in a Clinical AD Trial 2009 ·American Journal of Alzheimer s Disease & Other Dementias® ·Jeffrey Sevigny, Yahong Peng, Lian Liu, Christopher R. Lines	15
12	Early risk assessment for Alzheimer's disease 2009 ·Alzheimer s & Dementia ·María C. Carrillo, Andrew D. Blackwell, Harald Hampel, (unknown), Reisa A. Sperling, Dale Schenk, Jeffrey Sevigny, Steven H. Ferris, David A. Bennett, Suzanne Craft, Timothy Hsu, William E. Klunk	30
13	Growth hormone secretagogue MK-677 2008 ·Neurology ·Jeffrey Sevigny, (unknown), C H van Dyck, Yahong Peng, Christopher R. Lines, Michael L. Nessly	73
14	An Evaluation of Neurocognitive Status and Markers of Immune Activation as Predictors of Time to Death in Advanced HIV Infection 2007 ·Archives of Neurology ·Jeffrey Sevigny, Steven M. Albert, Michael McDermott, Giovanni Schifitto, Justin C. McArthur, Ned Sacktor, Katherine Conant, Ola A. Selnes, Yaakov Stern, Daniel McClernon, Donna Palumbo, Karl Kieburtz, (unknown), Bruce A. Cohen, Karen Marder, Leon G. Epstein	82
15	HIV encephalitis simulating Huntington's disease 2005 ·Movement Disorders ·Jeffrey Sevigny, Steven S. Chin, (unknown), Mark W. Albers, Marc L. Gordon, Karen Marder	7
16	Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia 2004 ·Neurology ·Jeffrey Sevigny, Steven M. Albert, Michael McDermott, Justin C. McArthur, Ned Sacktor, Kathy Conant, Giovanni Schifitto, Ola A. Selnes, Yaakov Stern, Daniel McClernon, Donna Palumbo, Karl Kieburtz, (unknown), Bevin Cohen, Leon G. Epstein, Karen Marder	159
17	Diet and muscle glycogen in vastus lateralis of runners training for the marathon. 1980 ·Annie Tremblay, Jeffrey Sevigny, M. Jobin, C. Allard	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact